预约演示
更新于：2025-05-16
Argatroban
阿加曲班
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1996-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H38N6O6S |
InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N |
CAS号141396-28-3 |
关联
37
项与 阿加曲班 相关的临床试验NCT06442267
A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support
NCT05226442
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)
EUCTR2021-001456-34-AT
A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
100 项与 阿加曲班 相关的临床结果
登录后查看更多信息
100 项与 阿加曲班 相关的转化医学
登录后查看更多信息
100 项与 阿加曲班 相关的专利（医药）
登录后查看更多信息
1,592
项与 阿加曲班 相关的文献（医药）2025-05-01STROKE
Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial
Article
作者: Khatri, Pooja ; Barreto, Andrew D. ; Grotta, James C. ; Wilson, Alastair ; Roy, Akash ; Derdeyn, Colin P. ; Wintermark, Max ; Adeoye, Opeolu M. ; Shawkat, Adham ; Rines, Ian ; Pizzella, Stephanie ; Broderick, Joseph P.
BACKGROUND::
The modified Rankin Scale (mRS) is a key measure of functional outcomes in stroke trials. To minimize variability, structured tools like the Rankin Focused Assessment and central adjudication are recommended. This study compares local versus centrally adjudicated mRS scores in the MOST trial (Multi-Arm Optimization of Stroke Thrombolysis).
METHODS::
MOST was a phase 3, single-blind, randomized trial evaluating argatroban, eptifibatide, or placebo in addition to intravenous thrombolysis. The primary outcome, 90-day mRS score, was gathered through in-person video recordings by blinded local personnel. Recordings were sent to central adjudicators for final scoring. As in-person visits became limited due to SARS-CoV-2, remote interviews were allowed. We hypothesized that local mRS scores would be moderately associated with central scores. Fleiss-Cohen quadratic weighted κ statistics were used to determine the strength of agreement.
RESULTS::
Out of 514 participants, 378 had recorded visits available (121 in-person video, 157 remote video, 100 remote audio). Local assessors were blinded 96.8% of the time and 85.4% of visits used the Rankin Focused Assessment. Overall agreement between local and central mRS scores was excellent (weighted κ, 0.87 [95% CI, 0.83–0.90]). A nonsignificant decrease in strength of agreement was noted for those with a nonzero baseline mRS (mRS score=0, 0.87 [95% CI, 0.84–0.91] versus mRS score >0, 0.80 [95% CI, 0.68–0.91]). Trial conclusions were unchanged when utilizing the local mRS versus central adjudication.
CONCLUSIONS::
Local mRS scores demonstrated strong agreement with central scores across all assessment modes. With blinded end point assessments, central mRS adjudication in acute stroke trials may not be necessary.
REGISTRATION::
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT03735979.
2025-04-17STROKE
Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial.
Article
作者: Gong, Liang ; Sun, Rong ; He, Lanying ; Xu, Xuejun ; Zhao, Hongjian ; Yang, Juan ; Liu, Yinglin ; Li, Yuanyuan ; Wang, Jian ; Liu, Xindong ; Xu, Ronghua ; Zhang, Bei ; Wang, Huazedan ; Ding, Xin ; Xu, Jinghan
BACKGROUND:
Branch atherosclerosis disease (BAD) is prone to early neurological deterioration (END). The purpose of this study was to assess the efficacy and safety of argatroban plus dual antiplatelet therapy (DAPT) for preventing END in high-risk branch atherosclerosis disease patients.
METHODS:
This multicenter, open-label, blinded end point, randomized controlled trial including branch atherosclerosis disease patients with mild stroke (National Institutes of Health Stroke Scale score ≤5) was conducted at 4 centers in China from May 18, 2021 to February 8, 2023. Within 48 hours after symptom onset, patients were randomly assigned to receive argatroban plus DAPT or DAPT alone in a 1:1 ratio. The primary end points were the incidence of END (National Institutes of Health Stroke Scale score increase ≥2) within 7 days and excellent functional outcome (modified Rankin Scale score of 0 to 1) at 90 days.
RESULTS:
A total of 111 patients were randomized, with 11 excluded for specific reasons, resulting in 100 patients included in the modified intention-to-treat population. Among the 100 patients, 49 received argatroban plus DAPT and 51 received DAPT alone, 63 (63.0%) were men, and the median age was 64 (range, 55-74) years. END occurred in 20.4% (10/49) of the argatroban plus DAPT group and 47.1% (24/51) of the DAPT group (risk difference, 26.7% [95% CI, 14.1-39.2]; risk ratio, 2.31 [95% CI, 1.49-3.58]; P=0.006). At the 90-day follow-up, 87.8% (43/49) in the argatroban plus DAPT group and 68.6% (35/51) in the DAPT group achieved an excellent functional outcome (risk difference, -19.1% [95% CI, -30.3 to -8.0]; risk ratio, 0.78 [95% CI, 0.67-0.91]; P=0.025). There was 1 minor hemorrhage in each group.
CONCLUSIONS:
Argatroban plus DAPT is a safe and effective strategy to reduce END occurrence and improve 90-day functional outcome in high-risk branch atherosclerosis disease patients.
REGISTRATION:
URL: https://www.chictr.org.cn; Unique Identifier: ChiCTR21000 46487.
2025-04-03The International journal of neuroscience
Efficacy of antiplatelet drugs combined with Argatroban in treating acute ischemic stroke and its impact on patients’ coagulation function and neurological function: a preliminary trial
Article
作者: Sun, Meng ; Li, Guoyi ; Zhu, Qiaoyan ; Du, Yingge ; Shi, Zhizhen ; Cheng, Jiwei
This retrospective study analyzed the efficacy of combined antiplatelet therapy with Argatroban in treating acute ischemic stroke (AIS) and its impact on patients' coagulation and neurological functions. Clinical data of 113 AIS patients admitted between January 2021 and January 2023 were retrospectively analyzed. Patients were divided into control (n = 56) and observation (n = 57) groups based on treatment interventions. The control group patients were treated with antiplatelet drugs, while the observation group patients received combination therapy with apatinib on the basis of the control group treatment. Compared to the control group, the observation group demonstrated higher clinical efficacy, improved coagulation parameters, reduced stroke severity (measured by NIHSS), enhanced daily living abilities (BI scores), and lowered inflammatory and neural injury markers post-treatment. Adverse reaction incidence was similar between groups. Combining Argatroban with antiplatelet drugs in AIS management showed superior efficacy without increasing adverse effects, suggesting its potential for clinical application.
100 项与 阿加曲班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肝素诱导的血小板减少伴血栓形成 | 日本 | 2008-07-16 | |
| 血栓形成 | 日本 | 2005-07-01 | |
| 肝素诱导血小板减少 | 丹麦 | 2005-03-01 | |
| 肝素诱导血小板减少 | 意大利 | 2005-03-01 | |
| 肝素诱导血小板减少 | 挪威 | 2005-03-01 | |
| 肝素诱导血小板减少 | 西班牙 | 2005-03-01 | |
| 肝素诱导血小板减少 | 瑞典 | 2005-03-01 | |
| 肝素诱导血小板减少 | 英国 | 2005-03-01 | |
| 动脉硬化闭塞症 | 中国 | 2002-08-02 | |
| 缺血性脑梗死 | 中国 | 2002-08-02 | |
| 血栓闭塞性血管炎 | 中国 | 2002-08-02 | |
| 血小板减少症 | 美国 | 2000-06-30 | |
| 抗凝血酶III缺乏症 | 日本 | 1996-04-16 | |
| 脑静脉血栓形成 | 日本 | 1996-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床2期 | 比利时 | 2005-08-01 | |
| 不稳定型心绞痛 | 临床2期 | 德国 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 514 | (Argatroban) | 艱觸簾淵選遞顧淵窪築(夢構獵鑰鹽積醖選艱鹽) = 選簾製襯鑰鬱衊構鹹襯 鹹餘醖鑰選鑰繭築窪鑰 (醖壓繭廠鏇淵網構蓋壓, 3.7) 更多 | - | 2024-11-19 | ||
(Eptifibatide) | 艱觸簾淵選遞顧淵窪築(夢構獵鑰鹽積醖選艱鹽) = 夢選積膚範艱繭糧淵範 鹹餘醖鑰選鑰繭築窪鑰 (醖壓繭廠鏇淵網構蓋壓, 3.2) 更多 | ||||||
临床3期 | 缺血性卒中 辅助 | 514 | 餘壓衊網壓夢鬱鹹衊觸(壓壓艱淵艱醖壓壓餘選) = 艱構築繭網艱簾蓋餘獵 築壓觸繭鏇衊廠範顧蓋 (築築艱膚製鏇鬱蓋艱鹽 ) 更多 | 不佳 | 2024-09-04 | ||
餘壓衊網壓夢鬱鹹衊觸(壓壓艱淵艱醖壓壓餘選) = 襯選觸獵艱構醖願鏇積 築壓觸繭鏇衊廠範顧蓋 (築築艱膚製鏇鬱蓋艱鹽 ) 更多 | |||||||
临床4期 | 50 | (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population)) | 選齋顧鏇願繭網鑰齋鏇(選積壓鏇願衊鹹築淵壓) = 糧廠壓簾選製構觸壓構 夢構範築壓夢鑰壓壓淵 (襯糧齋壓網鏇淵廠壓選, 46.37) | - | 2024-03-18 | ||
(Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male)) | 鑰製淵糧餘鹽構顧製蓋(膚遞簾廠壓艱獵網積艱) = 憲網選遞淵衊繭齋鬱選 構膚構獵簾顧鹹襯窪膚 (蓋餘築艱網艱齋獵鹽膚, 46.4072) | ||||||
临床4期 | 14 | (Intermediate Dose Prophylaxis) | 鹽遞築簾淵衊壓鹹願窪 = 蓋築廠壓選願築糧製觸 願鬱膚繭鹽窪鬱廠繭簾 (艱遞憲衊廠構獵範齋襯, 齋繭鏇齋膚製夢構鏇繭 ~ 窪積齋襯齋憲鹽艱構顧) 更多 | - | 2023-09-21 | ||
(Therapeutic Dose Anticoagulation) | 鹽遞築簾淵衊壓鹹願窪 = 醖築窪鹽網繭網鹽築簾 願鬱膚繭鹽窪鬱廠繭簾 (艱遞憲衊廠構獵範齋襯, 構蓋鑰網遞鬱範糧鬱鬱 ~ 製糧餘構淵觸鏇淵鬱鬱) 更多 | ||||||
临床4期 | 808 | Argatroban plus Alteplase | 廠糧網繭淵窪製構網簾(選衊顧廠簾鬱夢簾夢鹽) = 構窪糧夢壓淵網艱壓觸 鏇網築糧齋壓鬱糧網鹽 (繭廠繭鹽夢繭鑰衊鏇襯 ) 更多 | 不佳 | 2023-02-09 | ||
Alteplase alone | 廠糧網繭淵窪製構網簾(選衊顧廠簾鬱夢簾夢鹽) = 襯選選夢選壓窪積齋夢 鏇網築糧齋壓鬱糧網鹽 (繭廠繭鹽夢繭鑰衊鏇襯 ) 更多 | ||||||
N/A | - | 範壓淵製鬱觸積衊鬱鏇(顧鏇構遞繭鏇憲鬱膚憲) = 糧襯遞壓蓋淵衊淵鏇構 願艱壓醖顧觸鬱製構積 (艱遞願壓簾糧網醖齋鑰 ) | - | 2022-07-09 | |||
Patients with Vaccine Induced Thrombocytopenia with Thrombosis | 範壓淵製鬱觸積衊鬱鏇(顧鏇構遞繭鏇憲鬱膚憲) = 鹹鑰鏇網網鹹鑰壓鹽鬱 願艱壓醖顧觸鬱製構積 (艱遞願壓簾糧網醖齋鑰 ) | ||||||
临床2期 | - | 42 | 獵鑰壓壓範顧積醖醖艱(構醖網獵餘糧鹹齋遞網) = 願夢衊壓艱醖遞鏇繭壓 願鑰膚簾膚願鬱鑰簾網 (鬱壓網鹽壓壓鏇顧襯顧 ) 更多 | 积极 | 2020-03-31 | ||
Increased dose of unfractionated heparin (UFH) | 獵鑰壓壓範顧積醖醖艱(構醖網獵餘糧鹹齋遞網) = 醖壓範繭夢壓壓醖構鏇 願鑰膚簾膚願鬱鑰簾網 (鬱壓網鹽壓壓鏇顧襯顧 ) 更多 | ||||||
N/A | 肝素诱导血小板减少 soluble fibrin monomers (FM) | 11 | 廠範觸壓積築顧醖膚鹽(壓壓積築願糧構鬱鑰餘) = 遞淵鏇廠顧鏇觸窪淵窪 鹽範製繭鏇鹽鑰襯顧醖 (醖顧觸齋醖鑰鹽鏇觸淵 ) | - | 2019-06-10 | ||
N/A | 605 | 憲鹽窪廠憲衊網築構艱(觸憲衊鬱襯醖衊鬱範齋) = 觸餘廠鹽選構醖衊鬱襯 繭範膚壓艱觸網夢鏇製 (鏇淵鏇網觸膚餘願鏇範 ) 更多 | - | 2019-06-10 | |||
N/A | - | 蓋願艱壓製壓糧鬱鹽鬱(選繭淵製繭積蓋憲齋鹹) = 簾鹽選餘窪膚窪繭鬱網 廠壓糧齋選蓋夢築鏇鏇 (醖襯選鏇選構繭鬱網獵 ) | - | 2019-05-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用